Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease,is a specific disease that causes the death of neurons controlling voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. It may begin with weakness in the arms or legs, or with difficulty speaking or swallowing. About half of the people affected develop at least mild difficulties with thinking and behavior and most people experience pain. Most eventually lose the ability to walk, use their hands, speak, swallow, and breathe.
Components of the Book:
- Chapter1
Big data of clinical manifestations combined
with neuroelectrophysiologic features in the early diagnosis of motor
neuron disease
- Chapter2
The transcript expression levels of HNRNPM, HNRNPA0
and AKAP17A splicing factors may be predictively
associated with ageing phenotypes in human peripheral
blood
- Chapter3
Brugada syndrome in a patient with amyotrophic lateral sclerosis: a case report
- Chapter4
Carnitine deficiency presenting with a decreased mental state in a patient with amyotrophic lateral sclerosis receiving long-term tube feeding: a case report
- Chapter5
A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson’s Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity
- Chapter6
Therapy of Sialorrhea with Botulinum Neurotoxin
- Chapter7
The endotoxin hypothesis of neurodegeneration
- Chapter8
Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database
- chapter9
Serial ultrasound assessment of diaphragmatic function and clinical outcome in patients with amyotrophic lateral sclerosis
- chapter10
Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis
- chapter11
Differentiation of Mesenchymal Stem Cells to Neuroglia: in the Context of Cell Signalling
- chapter12
Factors predicting one-year mortality in amyotrophic lateral sclerosis patients – data from
a population-based registry
- chapter13
Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis
- Chapter14
Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with
and without amyotrophic lateral sclerosis
- Chapter15
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
Readership:
Students, academics, teachers and other people attending or interested in medicine or health care.
P. M. Fernandes, Centre for Clinical Brain Sciences University of Edinburgh, Edinburgh, UK
M. R. Macleod, Centre for Clinical Brain Sciences University of Edinburgh & NHS Forth Valley Edinburgh, UK
A. Bateman, Department of Critical Care Medicine, Western General Hospital, Edinburgh, UK
Pal , Centre for Clinical Brain Sciences, Anne Rowling Regenerative Neurology Clinic, and Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh & NHS Forth Valley, Edinburgh, UK
Abrahams , Psychology – School of Philosophy, Psychology and Language Sciences, Anne Rowling Regenerative Neurology Clinic, and Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK
James R Williams, Biogen Idec, Cambridge, USA
and more...